Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Semin Radiat Oncol. 2010 Oct;20(4):267-273.e3. doi: 10.1016/j.semradonc.2010.05.001.
Radiotherapy for the treatment of cancer can cause a wide range of cellular effects, the most biologically potent of which is the double-strand break in DNA. The process of repairing DNA double-strand breaks involves 1 of 2 major mechanisms: nonhomologous end joining or homologous recombination. In this review, we review the molecular mechanisms of homologous recombination, in particular as it relates to the repair of DNA damage from ionizing radiation. We also present specific situations in which homologous recombination may be dysfunctional in human cancers and how this functional abnormality can be recognized. We also discuss the therapeutic opportunities that can be exploited based on deficiencies in homologous recombination at various steps in the DNA repair pathway. Side-by-side with these potential therapeutic opportunities, we review the contemporary clinical trials in which strategies to exploit these defects in homologous recombination can be enhanced by the use of radiotherapy in conjunction with biologically targeted agents. We conclude that the field of radiation oncology has only scratched the surface of a potentially highly efficacious therapeutic strategy.
放射治疗癌症可引起广泛的细胞效应,其中生物学作用最强的是 DNA 的双链断裂。修复 DNA 双链断裂涉及两种主要机制之一:非同源末端连接或同源重组。在这篇综述中,我们回顾了同源重组的分子机制,特别是它与修复电离辐射引起的 DNA 损伤的关系。我们还介绍了同源重组在人类癌症中可能出现功能障碍的特定情况,以及如何识别这种功能异常。我们还讨论了基于 DNA 修复途径中同源重组各个步骤的缺陷而可以利用的治疗机会。与这些潜在的治疗机会并列的是,我们回顾了在当代临床试验中,通过放射治疗与生物靶向药物联合使用,可以增强利用同源重组缺陷的策略。我们得出结论,放射肿瘤学领域仅仅触及了一种潜在的高效治疗策略的表面。